Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Apellis Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
APLS
Nasdaq
8731
https://apellis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Apellis Pharmaceuticals Inc
Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
- May 9th, 2024 10:34 am
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
- May 8th, 2024 4:26 pm
Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- May 8th, 2024 10:15 am
Apellis Pharmaceuticals Inc (APLS) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
- May 8th, 2024 7:13 am
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
- May 7th, 2024 3:19 pm
Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- May 7th, 2024 1:30 pm
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
- May 7th, 2024 12:15 pm
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- May 7th, 2024 11:05 am
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- May 6th, 2024 11:00 am
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
- May 1st, 2024 2:01 pm
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- May 1st, 2024 11:00 am
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
- Apr 30th, 2024 2:00 pm
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
- Apr 26th, 2024 11:15 am
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
- Apr 23rd, 2024 11:00 am
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 4th, 2024 8:05 pm
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 1st, 2024 11:00 am
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
- Mar 28th, 2024 3:30 pm
Insider Sell: Chief Business & Strategy Officer Mark Delong Sells 9,913 Shares of Apellis ...
- Mar 19th, 2024 11:01 pm
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
Apellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 Shares
- Mar 14th, 2024 11:02 pm
Scroll